SUPERNUS PHARMACEUTICALS, INC. Cost of Revenue
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Cost of Revenue of $33.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $33.67M, a 100.09% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $23.39M, a 48.39% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $23.01M, a 11.84% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $18.96M, a 7.86% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2025 was $74.56M, a 4.29% decline from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2024 was $77.91M, a 7.01% decline from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2023 was $83.78M, a 3.95% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2022 was $87.22M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.67M 10-Q · filed 2026-08-03 | $57.06M 10-Q · filed 2026-08-03 | $80.07M derived: sum of 3 quarters · filed 2026-08-03 | $99.03M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $23.39M 10-Q · filed 2026-05-05 | $46.40M derived: sum of 2 quarters · filed 2026-05-05 | $65.36M derived: sum of 3 quarters · filed 2026-05-05 | $82.19M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $23.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $41.97M derived: sum of 2 quarters · filed 2026-03-02 | $58.80M derived: sum of 3 quarters · filed 2026-08-03 | $74.56M 10-K · filed 2026-03-02 |
| 2025-09-30 | $18.96M 10-Q · filed 2025-11-06 | $35.79M derived: sum of 2 quarters · filed 2026-08-03 | $51.55M 10-Q · filed 2025-11-06 | $77.65M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $16.83M 10-Q · filed 2026-08-03 | $32.59M 10-Q · filed 2026-08-03 | $58.69M derived: sum of 3 quarters · filed 2026-08-03 | $76.27M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $15.76M 10-Q · filed 2026-05-05 | $41.86M derived: sum of 2 quarters · filed 2026-05-05 | $59.44M derived: sum of 3 quarters · filed 2026-05-05 | $77.36M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $26.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $43.68M derived: sum of 2 quarters · filed 2026-03-02 | $61.60M derived: sum of 3 quarters · filed 2026-03-02 | $77.91M 10-K · filed 2026-03-02 |
| 2024-09-30 | $17.58M 10-Q · filed 2025-11-06 | $35.50M derived: sum of 2 quarters · filed 2025-11-06 | $51.81M 10-Q · filed 2025-11-06 | $71.44M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $17.92M 10-Q · filed 2025-08-05 | $34.23M 10-Q · filed 2025-08-05 | $53.85M derived: sum of 3 quarters · filed 2026-03-02 | $73.45M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $16.31M 10-Q · filed 2025-05-06 | $35.94M derived: sum of 2 quarters · filed 2026-03-02 | $55.54M derived: sum of 3 quarters · filed 2026-03-02 | $76.63M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $19.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $39.23M derived: sum of 2 quarters · filed 2026-03-02 | $60.32M derived: sum of 3 quarters · filed 2026-03-02 | $83.78M 10-K · filed 2026-03-02 |
| 2023-09-30 | $19.60M 10-Q · filed 2024-11-04 | $40.69M derived: sum of 2 quarters · filed 2024-11-04 | $64.15M 10-Q · filed 2024-11-04 | $87.11M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $21.09M 10-Q · filed 2024-08-06 | $44.55M 10-Q · filed 2024-08-06 | $67.50M derived: sum of 3 quarters · filed 2025-02-25 | $93.38M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $23.46M 10-Q · filed 2024-05-08 | $46.41M derived: sum of 2 quarters · filed 2025-02-25 | $72.29M derived: sum of 3 quarters · filed 2025-02-25 | $92.75M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $22.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $48.83M derived: sum of 2 quarters · filed 2025-02-25 | $69.29M derived: sum of 3 quarters · filed 2025-02-25 | $87.22M 10-K · filed 2025-02-25 |
| 2022-09-30 | $25.88M 10-Q · filed 2023-11-08 | $46.34M derived: sum of 2 quarters · filed 2023-11-08 | $64.27M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $20.46M 10-Q · filed 2023-08-08 | $38.39M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $17.93M 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | $18.09M 10-Q · filed 2022-11-09 | $43.11M derived: sum of 2 quarters · filed 2022-11-09 | $58.07M 10-Q · filed 2022-11-09 | $76.60M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $25.03M 10-Q · filed 2022-08-08 | $39.98M 10-Q · filed 2022-08-08 | $58.52M derived: sum of 3 quarters · filed 2022-08-08 | $79.90M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $14.95M 10-Q · filed 2022-05-12 | $33.49M derived: sum of 2 quarters · filed 2022-05-12 | $54.88M derived: sum of 3 quarters · filed 2022-05-12 | $63.26M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $18.53M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $39.92M derived: sum of 2 quarters · filed 2021-11-05 | $48.31M derived: sum of 3 quarters · filed 2021-11-05 | $52.46M 10-K · filed 2021-03-08 |
| 2020-09-30 | $21.39M 10-Q · filed 2021-11-05 | $29.77M derived: sum of 2 quarters · filed 2021-11-05 | $33.93M 10-Q · filed 2021-11-05 | $38.04M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $8.39M 10-Q · filed 2021-08-06 | $12.54M 10-Q · filed 2021-08-06 | $16.65M derived: sum of 3 quarters · filed 2021-08-06 | $21.47M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $4.15M 10-Q · filed 2021-05-07 | $8.27M derived: sum of 2 quarters · filed 2021-05-07 | $13.08M derived: sum of 3 quarters · filed 2021-05-07 | $17.13M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $4.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $8.93M derived: sum of 2 quarters · filed 2021-03-08 | $12.98M derived: sum of 3 quarters · filed 2021-03-08 | $16.66M 10-K · filed 2021-03-08 |
| 2019-09-30 | $4.82M 10-Q · filed 2020-11-06 | $8.86M derived: sum of 2 quarters · filed 2020-11-06 | $12.55M 10-Q · filed 2020-11-06 | $16.73M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | $4.04M 10-Q · filed 2020-08-17 | $7.73M 10-Q · filed 2020-08-17 | $11.92M derived: sum of 3 quarters · filed 2021-03-08 | $16.12M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | $3.68M 10-Q · filed 2020-05-15 | $7.87M derived: sum of 2 quarters · filed 2021-03-08 | $12.08M derived: sum of 3 quarters · filed 2021-03-08 | $15.76M derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $8.39M derived: sum of 2 quarters · filed 2021-03-08 | $12.08M derived: sum of 3 quarters · filed 2021-03-08 | $15.36M 10-K · filed 2021-03-08 |
| 2018-09-30 | $4.21M 10-Q · filed 2019-11-08 | $7.89M derived: sum of 2 quarters · filed 2019-11-08 | $11.17M 10-Q · filed 2019-11-08 | $15.32M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $3.68M 10-Q · filed 2019-08-09 | $6.96M 10-Q · filed 2019-08-09 | $11.12M derived: sum of 3 quarters · filed 2020-02-28 | $15.37M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $3.28M 10-Q · filed 2019-05-10 | $7.43M derived: sum of 2 quarters · filed 2020-02-28 | $11.68M derived: sum of 3 quarters · filed 2020-02-28 | $15.54M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $8.41M derived: sum of 2 quarters · filed 2020-02-28 | $12.27M derived: sum of 3 quarters · filed 2020-02-28 | $15.21M 10-K · filed 2020-02-28 |
| 2017-09-30 | $4.25M 10-Q · filed 2018-11-09 | $8.11M derived: sum of 2 quarters · filed 2018-11-09 | $11.06M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $3.86M 10-Q · filed 2018-08-09 | $6.81M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $2.95M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $11.99M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |